The global short bowel syndrome market size surpassed at US$ 1.24 billion in 2022 and expected to reach US$ 16.83 billion by 2032 with a CAGR of 29.8% from 2023 to 2032.
The global short bowel syndrome market size surpassed at US$ 1.24 billion in 2022 and expected to reach US$ 16.83 billion by 2032 with a CAGR of 29.8% from 2023 to 2032. The global market is driven by increase in awareness and acceptance of the short bowel syndrome treatment.
Immediate Delivery Available | Get the sample copy of report@ https://www.visionresearchreports.com/report/sample/35727
Demand for Glucagon-like Peptide-2 (GLP-2) for Treatment of Short Bowel Syndrome
In terms of drug class, the glucagon-like peptide-2 (GLP-2) is expected to be the leading segment of the short bowel syndrome market during the forecast period. The only available GLP-2 analog in the market for the treatment of short bowel syndrome is Gattex/Revestive. The strong growth of this segment can be attributed to the increase in prescriptions for the Gattex therapy, rise in the number of patients on Gattex therapy, and high cost of the drug. This drug is commercially available in North America and selected countries in Europe, including the U.K., Germany, France, Italy, Spain, and Nordics. Furthermore, this compound was awarded orphan drug status in Japan in 2014 and is in Phase III clinical trials.
Gattex has been awarded the orphan drug exclusivity until 2022 in the U.S. and until 2024 in Europe, which prevents the launch of drugs based on the same active particle in these regions. This would enhance the revenue generated by the sale of Gattex/Revestive and strengthen its market share. The market for GLP-2 analog is projected to grow, owing to its ability to reduce the patients’ dependence on parenteral nutrition.
Growth Hormone Approved for Treatment of Short Bowel Syndrome
Growth hormone approved for the treatment of short bowel syndrome is Zorbtive. The growth hormone drug class segment is anticipated to expand at a meagre CAGR, owing to its patent expiry. Furthermore, the glutamine approved for the treatment of short bowel syndrome, NutreStore, is administered to patients who are on specialized nutrition, in conjunction with the growth hormone approved for this indication.
The market for other drugs used for the treatment of short bowel syndrome is expected to record modest growth. This can be attributed to their usage in the treatment of symptoms associated with short bowel syndrome. Other drugs used include anti-diarrheal (to treat the primary symptom of short bowel syndrome, diarrhea), proton pump inhibitors (used to treat gastric acid secretions), and H-2 receptor blockers. These drugs are administered to a patient, along with nutritional support.
Increase in Clinical Trials or Pipeline Drugs for Short Bowel Syndrome Treatment to Propel Market
Strong pipeline drugs for short bowel syndrome are anticipated to provide tremendous growth opportunities for the market in the near future. Pipeline drugs such as Zealand Pharma’s Glepaglutide (ZP1848), a long acting GLP-2 analog for short bowel syndrome, is in phase III clinical trials, results of which is expected in 2021. Pipeline drugs for short bowel syndrome act as a driver for the short bowel syndrome market. The late stage clinical development pipeline consists of several first-in-class drugs that are effective and safe for short bowel syndrome patients. Once these drugs are launched, the short bowel syndrome market is expected to witness growth at a significant rate, owing to better efficacy than their current counterparts.
North America to Lead Short Bowel Syndrome Market
North America was the dominant region in the short bowel syndrome market and is expected to lead the market during the forecast period. The robust growth of the short bowel syndrome market in North America can be mainly attributed to the increase in prescriptions of Gattex therapy in the U.S. In addition, growth hormone and glutamine have been approved for the treatment of short bowel syndrome only in the U.S.
Pre-marketing strategies adopted by short bowel syndrome market players to create awareness about the syndrome and its treatment also contribute to the market expansion in North America. For instance, prior to the launch of Gattex, NPS Pharmaceuticals (now Shire acquired by Takeda Pharmaceutical Company Limited), utilized an unbranded educational website, ShortBowelSupport.com, to raise awareness among patients, families, and healthcare professionals. Europe is expected to be the second major region in the short bowel syndrome market, owing to the approval of Revestive in the region and increase in awareness among people.
Immediate Delivery Available | Buy this Premium Research Report@ https://www.visionresearchreports.com/report/checkout/35727
Key Segments
- In terms of drug class, the short bowel syndrome market has been categorized into glucagon-like peptide-2 (GLP-2), growth hormone, glutamine, and others. Parenteral nutrition reduces the risk of malnutrition and dehydration and gradually, the patients can be weaned off parenteral nutrition based on intestinal adaptation.
- The primary aim of the treatment of SBS patients includes restoring fluid and electrolyte balance. Glucagon-like Peptide-2 (GLP-2) approved for the indication is administered to the patients who are on parenteral nutrition. It is an antisecretory, transit modulating, and intestinotrophic agents that enable the treatment of SBS. Intestinotrophic effects of GLP-2 are mediated by increase in the proliferation of intestinal crypt cells; increase in villous height in jejunum, duodenum, and ileum; and enterocyte proliferation in the jejunal crypt.
- This GLP-2 aided increase in intestinal cell mass aids in mucosal growth, enhances activities of intestinal brush-border enzymes, delays the gastric transit, and increases the intestinal capacity for nutrient absorption
- In addition, the GLP-2 analog differs from the natural GLP-2 by a single amino acid, where an alanine is replaced by a glycine. This structural difference increases the half-life of the GLP-2 analog to two hours as compared to seven minutes half-life of the natural GLP-2.
- GLP-2 analog is also resistant to degradation by dipeptidyl peptidase-IV (DDP-IV). These features make it the most preferred mode of treatment available for SBS patients. This is likely to drive the short bowel syndrome market during the forecast period.
- The market size and forecast for each of the segments have been provided in terms of US$ Mn from 2019 to 2032, along with their respective CAGRs for the forecast period from 2022 to 2032, considering 2022 as the base year
Regional Outlook
- Geographically, the short bowel syndrome market has been segmented into four major regions: North America (U.S. and Canada), Europe (U.K., Germany, France, Spain, Italy, and Rest of Europe), Japan, and Rest of the World (India, China, Australia & New Zealand, Brazil, and Middle East)
- The market size and forecast for each of these regions and the mentioned countries/sub-regions have been provided for the period from 2019 to 2032, along with their respective CAGRs for the forecast period from 2023 to 2032, considering 2022 as the base year. The research study also covers the competitive scenario in these regions.
Related Reports
- Dry Eye Syndrome Treatment Market - https://www.visionresearchreports.com/dry-eye-syndrome-treatment-market/39754
- Autism Spectrum Disorder Treatment Market - https://www.visionresearchreports.com/autism-spectrum-disorder-treatment-market/39768
- Non-invasive Ventilators Market - https://www.visionresearchreports.com/non-invasive-ventilators-market/39375
Companies Mentioned in Report
- The report also profiles following mentioned major players in the short bowel syndrome market based on various attributes such as company overview, financial overview, treatment types, business strategies, and recent developments. The companies include
- Shire plc (Takeda Pharmaceutical Company Limited)
- Zealand Pharma A/S
- Sancilio & Company, Inc.
- OxThera
- Nutrinia Ltd.
- Ardelyx, Inc.
- Emmaus Life Sciences, Inc.
- GLyPharma Therapeutic, Inc. (Pfizer Inc.)
- Merck KGaA
- Naia Pharmaceuticals, Inc.
Market Segmentation
By Drug Class
-
- Glucagon-like Peptide-2 (GLP-2)
- Growth Hormone
- Glutamine
- Others
By Region
-
- North America
- Europe
- Japan
- Rest of the World
Click Here to View Full Report Table of Contents
Immediate Delivery Available | Buy this Premium Research Report@ https://www.visionresearchreports.com/report/checkout/35727
You can place an order or ask any questions, please feel free to contact at sales@visionresearchreports.com | +1 9197 992 333